Key result
Cancer and cardiovascular diseases share concurrent metabolic alterations and signaling pathways, which mediate a direct maladaptive crosstalk leading to cachexia and cardiac dysfunction.
Why the study?
Cancer biology may directly affect the heart beyond cardiotoxic chemotherapy side effects, with emerging interest in the metabolic crosstalk between cancer and heart failure.
Cancer and heart failure share concurrent metabolic alterations and inflammatory pathways that mediate a maladaptive crosstalk, contributing to cardiac wasting and increased mortality.
Answers are grounded in this paper and cite their sources.
Suggests cancer biology may affect cardiac metabolism; leaves open mechanisms and clinical relevance pending prospective data.
Cardiovascular diseases have multifactorial causes. Classical cardiovascular risk factors, such as arterial hypertension, smoking, hyperlipidemia, and diabetes associate with the development of vascular stenoses and coronary heart disease. Further comorbidities and its impact on cardiovascular metabolism have gotten more attention recently. Thus, also cancer biology may affect the heart, apart from cardiotoxic side effects of chemotherapies. Cancer is a systemic disease which primarily leads to metabolic alterations within the tumor. An emerging number of preclinical and clinical studies focuses on the interaction between cancer and a maladaptive crosstalk to the heart. Cachexia and sarcopenia can have dramatic consequences for many organ functions, including cardiac wasting and heart failure. These complications significantly increase mortality and morbidity of heart failure and cancer patients. There are concurrent metabolic changes in fatty acid oxidation (FAO) and glucose utilization in heart failure as well as in cancer, involving central molecular regulators, such as PGC-1α. Further, specific inflammatory cytokines (IL-1β, IL-6, TNF-α, INF-β), non-inflammatory cytokines (myostatin, SerpinA3, Ataxin-10) and circulating metabolites (D2-HG) may mediate a direct and maladaptive crosstalk of both diseases. Additionally, cancer therapies, such as anthracyclines and angiogenesis inhibitors target common metabolic mechanisms in cardiomyocytes and malignant cells. This review focuses on cardiovascular, cancerous, and cancer therapy-associated alterations on the systemic and cardiac metabolic state.
No takes yet. Share an insight, caveat, or question.
Finke et al. (2021) conducted a review in Cancer and Cardiovascular Disease. Cancer and cardiovascular diseases share concurrent metabolic alterations and signaling pathways, which mediate a direct maladaptive crosstalk leading to cachexia and cardiac dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: